ATE397921T1 - Neue verwendung von frk-tyrosinekinase inhibitoren - Google Patents

Neue verwendung von frk-tyrosinekinase inhibitoren

Info

Publication number
ATE397921T1
ATE397921T1 AT02720710T AT02720710T ATE397921T1 AT E397921 T1 ATE397921 T1 AT E397921T1 AT 02720710 T AT02720710 T AT 02720710T AT 02720710 T AT02720710 T AT 02720710T AT E397921 T1 ATE397921 T1 AT E397921T1
Authority
AT
Austria
Prior art keywords
frk
tyrosine kinase
relates
inhibitor
type
Prior art date
Application number
AT02720710T
Other languages
English (en)
Inventor
Michael Welsh
Cecilia Anneren
Original Assignee
Innoventus Project Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innoventus Project Ab filed Critical Innoventus Project Ab
Application granted granted Critical
Publication of ATE397921T1 publication Critical patent/ATE397921T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02720710T 2001-04-06 2002-04-05 Neue verwendung von frk-tyrosinekinase inhibitoren ATE397921T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0101230A SE0101230L (sv) 2001-04-06 2001-04-06 Ny användning av en tyrosinkinasinhibitor

Publications (1)

Publication Number Publication Date
ATE397921T1 true ATE397921T1 (de) 2008-07-15

Family

ID=20283697

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02720710T ATE397921T1 (de) 2001-04-06 2002-04-05 Neue verwendung von frk-tyrosinekinase inhibitoren

Country Status (7)

Country Link
US (1) US20040171563A1 (de)
EP (1) EP1372621B1 (de)
AT (1) ATE397921T1 (de)
DE (1) DE60227058D1 (de)
DK (1) DK1372621T3 (de)
SE (1) SE0101230L (de)
WO (1) WO2002080894A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060094682A1 (en) * 2004-10-29 2006-05-04 Odyssey Thera, Inc. Kinase inhibitors for the treatment of diabetes and obesity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177401B1 (en) * 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
GB9721437D0 (en) * 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
BR0212435A (pt) * 2001-09-10 2004-08-17 Sugen Inc Derivados de 3-(4,5,6,7-tetraidroindol-2-ilmetilideno)-2-indolinona como inibidores de cinase

Also Published As

Publication number Publication date
SE0101230L (sv) 2002-10-07
DK1372621T3 (da) 2008-10-20
EP1372621B1 (de) 2008-06-11
DE60227058D1 (de) 2008-07-24
EP1372621A1 (de) 2004-01-02
US20040171563A1 (en) 2004-09-02
SE0101230D0 (sv) 2001-04-06
WO2002080894A1 (en) 2002-10-17

Similar Documents

Publication Publication Date Title
IS7753A (is) Beta-amínó heterósýklískir dípeptidýl peptíðasa hindrar til meðhöndlunar á, eða til að fyrirbyggja,sykursýki
NO20083026L (no) Terapeutisk middel for diabetes
MY127961A (en) Beta-amino heterocyclic dipetidyl peptidase inhibitors for the treament or prevention of diabetes
DE60310991D1 (de) Phenylalaninderivate als hemmer der dipeptidyl peptidase zur behandlung oder prävention von diabetes
YU34404A (sh) N-supstituisani derivati pirolidina kao inhibitori dipeptidil-peptidaze iv
EP1490335A4 (de) Heterocyclische beta-aminoverbindungen als inhibitoren der dipeptidylpeptidase zur behandlung bzw. prävention von diabetes
UA88257C2 (ru) ПРИМЕНЕНИЕ ИНГИБИТОРА ПРОТЕИНКИНАЗЫ С-α ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ПОЧЕК, КОТОРЫЕ ПРИВОДЯТ К ПРОТЕИНУРИИ, И ДИАБЕТИЧЕСКИМ РЕТИНОПАТИИ, НЕВРОПАТИИ ИЛИ НЕФРОПАТИИ
EP1794120A4 (de) Peptidaseinhibitoren
HRP20050287A2 (en) Indole-3-carboxamides as glucokinase (gk) activators
EP1554280A4 (de) Antidiabetische heterocyclische beta-aminoverbindungen als inhibitoren von dipeptidylpeptidase
DE60330485D1 (de) Zur behandlung von diabetes
ATE537152T1 (de) Verbindungen, ihre pharmazeutischen zusammensetzungen und ihre verwendung in der behandlung von stoffwechselstörungen
EA199901086A1 (ru) ХИНОЛИНОВЫЕ И ХИНОКСАЛИНОВЫЕ СОЕДИНЕНИЯ, ИНГИБИРУЮЩИЕ ТИРОЗИНКИНАЗЫ ТРОМБОЦИТАРНОГО ФАКТОРА РОСТА И/ИЛИ p56
NO20091596L (no) Benzoylamino-heterocykliske forbindelser som Glucokinase-(GLK)-activatorer
DE60110054D1 (en) Cardioprotektive phosphonate
DK1143955T3 (da) En kombination af FBPase-inhibitorer og insulinsensibiliseringsmidler til behandling af diabetes
ATE397921T1 (de) Neue verwendung von frk-tyrosinekinase inhibitoren
ATE542542T1 (de) Verwendung von gp130 aktivatoren zur behandlung von diabetischer neuropathie
SE0200198D0 (sv) New use
SI1399156T1 (sl) Derivati alkiliden pirazolidindiona in njihova uporaba pri zdravljenju diabetesa in debelosti
AP2004003113A0 (en) Use of an inhibitor or antagonist against tissue factor
DE60312656D1 (de) Arzneimittel zur behandlung von störungen des zirkadianen rhythmus
DK1397124T3 (da) Anvendelse af diabetesmidler til fremstilling af et lægemiddel med helende virkning
WO2002023784A3 (en) Cysteine protease inhibitors
MY138965A (en) Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties